Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 1–24 of 286
NAD+ IV Therapy Supports Cellular Energy and DNA Repair
Aeon Clinic in Dubai offers intravenous NAD+ supplementation and micronutrient delivery, claiming support for metabolic function, DNA repair, and cognitive clarity through direct bloodstream administration. The clinical model emphasizes physician oversight and personalized protocols as distinguishing factors in the premium wellness space.
Stem Cell Banking Preserves Regenerative Capacity Before Age-Related Decline
A partnership between AcCELLerated Biologics and Forever Labs enables individuals to collect and cryopreserve their own adult stem cells while younger, creating a biological reserve for potential future regenerative therapies. This model shifts healthcare from reactive disease management toward proactive preservation of regenerative capacity during optimal biological windows.
Stem cell banking preserves youthful regenerative capacity
AcCELLerated Biologics and Forever Labs have partnered to integrate adult stem cell banking with autologous biologic therapies, combining PRP, adipose, and exosome products with cryopreserved stem cell services. This positions clinicians to offer patients access to preserved youthful stem cells for personalized regenerative medicine and sustained healthspan support.
Cellular Senescence and Senotherapeutics: The Expert Roundup
Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.
Senolytic Timing Matters: Sustained Clearance Outperforms Pulse Dosing
Senolytic treatment with dasatinib and quercetin in aged mice produced measurable remodeling across immune, fibrotic, and metabolic pathways, with sustained intervention showing greater efficacy than short-term exposure. This work maps the molecular cascades underlying senolytic action and establishes timing as a critical variable in cellular rejuvenation.
NAD+ IV Therapies Shift to Personalized Longevity Medicine
AEON Clinic in Dubai offers physician-supervised IV nutrient therapies and NAD+ treatments as part of a broader shift toward personalized health optimization focused on healthspan rather than lifespan. The clinic positions these interventions within longer-term health strategies rather than as standalone wellness experiences, reflecting emerging sophistication in how longevity medicine is being integrated into clinical practice.
Senescent Cell Clearance Unlocks Regenerative Therapy Efficacy
A preclinical study combining senescent cell clearance with stem cell-based regenerative therapy produced 70% lifespan extension in aged models, substantially outperforming either approach alone. The finding reinforces that addressing aging requires simultaneous intervention across multiple biological pathways rather than single-target strategies.
Plasma Exchange Removes Microplastics from Blood
Therapeutic plasma exchange reduced circulating microplastics by approximately 60% in patients with elevated baseline levels, achieving statistical significance (p < 0.001). This represents the first clinical evidence that a mechanical intervention can effectively remove microplastic particles from human blood.
Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming
Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.
Klotho Cell Therapy Advances to Regulatory Testing
Klothonova has completed a GMP-grade master cell bank of cells engineered to overexpress α-Klotho protein, advancing toward regulatory approval for an encapsulated cell therapy targeting aging and age-related disease. α-Klotho restoration represents a direct intervention in fundamental aging mechanisms that affect kidney function, neurodegeneration, and vascular integrity.
Mitochondria Delivery Method Rescues Parkinson’s in Mice
Researchers encapsulated healthy mitochondria in red blood cell membranes to deliver them into diseased cells, achieving efficient uptake and functional restoration across multiple cellular models of mitochondrial dysfunction. This addresses a long-standing barrier in mitochondrial replacement therapy and demonstrates potential for treating mitochondrial diseases and age-related energy decline.
Klotho Cell Therapy Restores Aging Protein via Encapsulation
Avaí Bio will present clinical data on an encapsulated cell therapy designed to restore circulating α-Klotho, a protein implicated in aging and metabolic regulation. The approach uses Austrianova's Cell-in-a-Box technology to sustain Klotho production, addressing a mechanism that declines with age and correlates with multiple age-related pathologies.
Klothea initiates longevity-focused human trial of klotho therapy
Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.
Springfield Wellness Center marks 25 years of NAD+ IV therapy
Springfield Wellness Center has operated for 25 years using intravenous NAD+ therapy as part of a multimodal protocol for addiction recovery and brain restoration. The clinic's longevity and expansion suggest sustained clinical utility, though the evidence base and mechanistic clarity for NAD+ infusions in longevity contexts remain limited.
Senescent cell clearance extends lifespan 70% in aged models
Immorta Bio's combined senolytic immunotherapy and regenerative cellular platform produced over 70% lifespan extension in aged animal models, alongside improvements in organ function, tissue repair, and markers of cellular recovery. The finding demonstrates that simultaneous clearance of senescent cells and activation of regenerative capacity can produce measurable gains in both lifespan and healthspan across multiple physiological domains.
Peptide Pharmacology: Evidence vs. Marketing in Longevity
Peptides represent a therapeutic class with genuine biological activity, requiring the same scrutiny applied to pharmaceutical interventions rather than supplements. The distinction between evidence-supported peptide applications and marketed claims determines whether they function as targeted tools or sources of unquantified risk.
Microcap produces anti-aging protein from encapsulated cells
Klothonova is developing an encapsulated cell therapy designed to restore circulating α-Klotho, a protein that declines with age and influences cardiovascular, renal, and cognitive function. The approach uses genetically modified cells housed in a biocompatible capsule to sustainably produce the protein, addressing a mechanism implicated in multiple age-related conditions.
Stem cell review targets diabetic wound healing
A systematic review and meta-analysis of allogeneic mesenchymal stromal cell therapies for diabetic foot ulcers found higher rates of complete wound closure and greater reductions in wound size compared to standard care, with no clear signal of serious treatment-related adverse events. The work demonstrates that regenerative cell therapies may support the body's repair capacity when conventional approaches alone prove insufficient in metabolic disease.
Senolytic Clearance Restores Lung Immunity in Aging
A correction to published research on senolytics—drugs that selectively eliminate senescent cells—clarifies dosing and outcome measures in aged mice infected with influenza. The findings support senolytics as a tool for reducing both acute and chronic inflammatory responses in aged lungs, with direct relevance to infection susceptibility in aging.
Cenegenics expands advanced plasma exchange services in Beverly Hills
Cenegenics has introduced selective plasma exchange technology designed to remove inflammatory proteins, metabolic byproducts, and environmental toxins while preserving beneficial plasma components. The service positions itself as a preventative intervention for individuals managing chronic environmental exposures and systemic inflammation.
Mitrix moves mitochondria into the clinic
Mitrix Bio has reported preliminary Phase 1 safety data from mitochondrial transplantation in two older adults with no observed adverse effects, while simultaneously launching clinics offering the intervention under Right to Try frameworks. This represents a transition from preclinical work to early clinical deployment, though data density remains limited relative to narrative momentum.
Senescent cell clearance and stem cell therapy extend lifespan 70%
A dual-therapy approach combining senescent cell clearance with mesenchymal stem cell restoration produced a 70% lifespan extension in mice, accompanied by sustained improvements in physiological function. This preclinical result demonstrates that coordinated interventions targeting cellular aging and tissue regeneration can produce measurable longevity gains.
Clearance of Senescent Cells by BCLXL‐PROTAC: A Novel Approach to Treat COPD?
BCL XL-PROTAC, a senolytic agent, selectively eliminates senescent cells in COPD airway tissue while promoting proliferation of healthy cells. This approach addresses a core driver of age-related lung disease and suggests a therapeutic pathway for restoring lung cell function in COPD patients.
Avaí Bio–Austrianova’s longevity protein program enters production
Avaí Bio and Austrianova have begun GMP-compliant production of a Master Cell Bank for genetically modified cells engineered to overexpress α-Klotho, a protein associated with improved cognitive resilience and organ function in aging. This transition from research to scalable manufacturing represents a critical step toward clinical cell therapy delivery for age-related disease.